4//SEC Filing
Campbell David Alan 4
Accession 0001415889-25-001165
CIK 0001817713other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 8:00 PM ET
Size
5.3 KB
Accession
0001415889-25-001165
Insider Transaction Report
Form 4
Campbell David Alan
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2025-01-07$60.00/sh−5,000$300,004→ 293,054 total
Footnotes (2)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.
- [F2]The weighted average sale price for the transaction reported was $60.0008 and the range of prices were between $60.00 and $60.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Documents
Issuer
Janux Therapeutics, Inc.
CIK 0001817713
Entity typeother
Related Parties
1- filerCIK 0001864158
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 8:00 PM ET
- Size
- 5.3 KB